|
1
|
Howell A, Anderson AS, Clarke RB, Duffy
SW, Evans DG, Garcia-Closas M, Gescher AJ, Key TJ, Saxton JM and
Harvie MN: Risk determination and prevention of breast cancer.
Breast Cancer Res. 16:4462014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bargostavan MH, Eslami G, Esfandiari N and
Shams Shahemabadi A: MMP9 promoter polymorphism (−1562C/T) does not
affect the serum levels of soluble MICB and MICA in breast cancer.
Iran J Immunol. 13:45–53. 2016.PubMed/NCBI
|
|
3
|
Kakarala M, Rozek L, Cote M, Liyanage S
and Brenner DE: Brenner Breast cancer histology and receptor status
characterization in Asian Indian and Pakistani women in the U. S.
-a SEER analysis. BMC Cancer. 10:1912010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang H, Yu Y, Jiang Z, Cao WM, Wang Z, Dou
J, Zhao Y, Cui Y and Zhang H: Next-generation proteasome inhibitor
MLN9708 sensitizes breast cancer cells to doxorubicin-induced
apoptosis. Sci Rep. 6:264562016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Palmieri C, Krell J, James CR,
Harper-Wynne C, Misra V, Cleator S and Miles D: Rechallenging with
anthracyclines and taxanes in metastatic breast cancer. Nat Rev
Clin Oncol. 7:561–574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu X, Fu Y, Wang Y, Wan S and Zhang J:
Gaining insight into crizotinib resistance mechanisms caused by
L2026M and G2032R mutations in ROS1 via molecular dynamics
simulations and free-energy calculations. J Mol Model. 23:1412017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guttman M and Rinn JL: Modular regulatory
principles of large non-coding RNAs. Nature. 482:339–346. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen LL and Zhao JC: Functional analysis
of long noncoding RNAs in development and disease. Adv Exp Med
Biol. 825:129–158. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu YR, Tang RX, Huang WT, Ren FH, He RQ,
Yang LH, Luo DZ, Dang YW and Chen G: Long noncoding RNAs in
hepatocellular carcinoma: Novel insights into their mechanism.
World J Hepatol. 7:2781–2791. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang T, Alvarez A, Hu B and Cheng SY:
Noncoding RNAs in cancer and cancer stem cells. Chin J Cancer.
32:582–593. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Deng G and Sui G: Noncoding RNA in
oncogenesis: A new era of identifying key players. Int J Mol Sci.
14:18319–18349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gökmen-Polar Y, Vladislav IT, Neelamraju
Y, Janga SC and Badve S: Prognostic impact of HOTAIR expression is
restricted to ER-negative breast cancers. Sci Rep. 5:87652015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhuang Y, Nguyen HT, Burow ME, Zhuo Y,
El-Dahr SS, Yao X, Cao S, Flemington EK, Nephew KP, Fang F, et al:
Elevated expression of long intergenic non-coding RNA. HOTAIR in a
basal-like variant of MCF-7 breast cancer cell. Mol Carcinog.
54:1656–1667. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yan J, Dang Y, Liu S, Zhang Y and Zhang G:
LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by
targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumour Biol.
21:235–256. 2015.
|
|
15
|
Austreid E, Lonning PE and Eikesdal HP:
The emergence of targeted drugs in breast cancer to prevent
resistance to endocrine treatment and chemotherapy. Expert Opin
Pharmacother. 15:681–700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mabuchi S, Kuroda H, Takahashi R and
Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in
ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee JJ, Loh K and Yap YS: PI3K/Akt/mTOR
inhibitors in breast cancer. Cancer Biol Med. 12:342–354.
2015.PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
Relative Gene Expression Data Using Real-Time Quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Amiri-Kordestani L, Basseville A, Kurdziel
K, Fojo AT and Bates SE: Targeting MDR in breast and lung cancer:
Discriminating its potential importance from the failure of drug
resistance reversal studies. Drug Resist Updat. 15:50–61. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia H, Truica CI, Wang B, Wang Y, Ren X,
Harvey HA, Song J and Yang JM: Immunotherapy for triple-negative
breast cancer: Existing challenges and exciting prospects. Drug
Resist Updat. 32:1–15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jang JE, Eom JI, Jeung HK, Cheong JW, Lee
JY, Kim JS and Min YH: Targeting AMPK-ULK1-mediated autophagy for
combating BET inhibitor resistance in acute myeloid leukemia stem
cells. Autophagy. 13:761–762. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang H, Chen Z, Wang X, Huang Z, He Z and
Chen Y: Long non-coding RNA: A new player in cancer. J Hematol
Oncol. 6:372013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Woo CJ and Kingston RE: HOTAIR lifts
noncoding RNAs to new levels. Cell. 129:1257–1259. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu Y, Lv F, Liang D, Yang Q, Zhang B, Lin
H, Wang X, Qian G, Xu J and You W: HOTAIR may regulate
proliferation, apoptosis, migration and invasion of MCF-7 cells
through regulating the P53/Akt/JNK signaling pathway. Biomed
Pharmacother. 90:555–561. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W,
De W, Wang Z and Wang R: The long noncoding RNA HOTAIR contributes
to cisplatin resistance of human lung adenocarcinoma cells via
downregualtion of p21(WAF1/CIP1) expression. PLoS One.
8:e772932013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang H, Qin R, Guan A, Yao Y, Huang Y, Jia
H, Huang W and Gao J: HOTAIR enhanced paclitaxel and doxorubicin
resistance in gastric cancer cells partly through inhibiting
miR-217 expression. J Cell Biochem. 119:7226–7234. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shang C, Guo Y, Zhang H and Xue YX: Long
noncoding RNA HOTAIR is a prognostic biomarker and inhibits
chemosensitivity to doxorubicin in bladder transitional cell
carcinoma. Cancer Chemother Pharmacol. 77:507–513. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li E, Zhao Z, Ma B and Zhang J: Long
noncoding RNA HOTAIR promotes the proliferation and metastasis of
osteosarcoma cells through the AKT/mTOR signaling pathway. Exp Ther
Med. 14:5321–5328. 2017.PubMed/NCBI
|
